Ondansetron Accordpharma (Ondansetron)

Ondansetron Accordpharma is a selective 5‑HT3 receptor antagonist used to manage nausea and vomiting in several clinical settings.

• Chemotherapy‑induced nausea and vomiting: helps prevent and control acute and delayed episodes in cancer patients.
• Radiation‑induced nausea and vomiting: reduces the frequency and severity of symptoms during radiotherapy.
• Post‑operative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures.
• Hyperemesis gravidarum (off‑label): may be considered when conventional therapies are ineffective, under specialist supervision.

• Ondansetron blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting these receptors, it prevents serotonin‑mediated activation of the vomiting centre, thereby reducing the initiation of nausea and vomiting signals.

Common Side Effects

• Headache: mild to moderate headache may occur.
• Constipation: reduced bowel movements are reported.
• Diarrhoea: occasional loose stools.
• Fatigue: feeling of tiredness or low energy.
• Dizziness: transient light‑headedness.
• Injection site reactions (if applicable): mild pain or erythema.

Serious or Rare Side Effects

• Cardiac arrhythmia: QT‑interval prolongation leading to irregular heart rhythm.
• Severe hypersensitivity: rash, itching, swelling, or anaphylaxis.
• Serotonin syndrome: agitation, tremor, hyperreflexia when combined with serotonergic agents.
• Hepatic dysfunction: elevated liver enzymes.
• Neuroleptic malignant‑like syndrome: rare, high fever and muscle rigidity.
• Vision changes: blurred vision or visual disturbances.

Ondansetron should be used with caution in patients with known cardiac conduction abnormalities or electrolyte disturbances.

• Cardiac monitoring: perform ECG in patients at risk for QT prolongation.
• Electrolyte assessment: correct hypokalemia, hypomagnesemia, or hypocalcemia before use.
• Drug interactions: review concomitant medications that may affect cardiac rhythm.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly indicated.
• Renal or hepatic impairment: dose adjustment may be required based on clinical judgment.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several medications that influence cardiac rhythm or serotonergic pathways.

Major Interactions (Avoid)

• Anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation.
• Certain antipsychotics (e.g., haloperidol, ziprasidone): additive effect on QT interval.
• Serotonergic drugs (e.g., SSRIs, MAO inhibitors): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness.
• Digoxin: potential increase in serum digoxin concentrations.
• Oral contraceptives: possible reduction in hormonal efficacy.
• Theophylline: may enhance theophylline toxicity.